Kyoto University And U.S. Izumi Bio Collaborate On iPS Research
This article was originally published in PharmAsia News
Executive Summary
Japan induced pluripotent stem cell research center Kyoto University signed a collaboration agreement with U.S. bioventure company iZumi Bio. The two will exchange information on creating human iPS cells using different methods and share analytic results on iPS cell's differentiation capabilities. Funded by major venture capital firms, iZumi obtained Bayer's iPS technology in February. Bayer had previously led Kyoto University in development and submitted the first patent application for iPS in Japan. (Click here for more - Japanese language
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.